The aim of the collaboration is to support the expansion of Quell’s autologous T-regulatory (Treg) cell therapy pipeline using Cellistic’s knowledge of iPSC processes. Under the terms of the deal, Quell Therapeutics and human induced pluripotent stem cell (iPSC) technology development and manufacturing firm Cellistic will take part in joint research to form a process for differentiating iPSCs into functional Treg cell therapy products. According to Quell, it will contribute its Treg expertise and technologies, as well as characterizing Treg…

Terumo Blood and Cell Technologies has won a $10.6 million contract from the US Government to continue freeze-dried plasma (FDP) development. Apheresis services firm Terumo Blood and Cell Technologies has entered into a contract with the Medical Technology Enterprise Consortium (MTEC), which is an Other Transaction Agreement (OTA) with the US Army Medical Research and Development Command. In 2016, Terumo was awarded initial funding of $1.9 million (potential to be increased to $16 million) from the US Government to support…